The National Center for Advancing Translational Sciences (NCATS) will soon be launching its first signature initiative, Discovering New Therapeutic Uses for Existing Molecules, which will give researchers access and funding to study compounds from Pfizer, AstraZeneca, and Eli Lilly that hit a roadblock after initial safety testing in humans. According to the NIH Extramural News: “Much like azidothymidine (AZT), which proved unsuccessful as a cancer drug but revolutionized HIV treatment, we hope that these molecules will be put to new therapeutic uses.”